Healthcare provider profile · identity verified

Craig Brown, DO

Family Practice · PORTLAND, MI · NPI 1295963932

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	538	155
Amlodipine Besylate	Amlodipine Besylate	419	125
Levothyroxine Sodium	Levothyroxine Sodium	393	114
Lisinopril	Lisinopril	368	107
Metoprolol Succinate	Metoprolol Succinate	350	101
Metformin Hcl	Metformin Hcl	308	102
Losartan Potassium	Losartan Potassium	271	76
Omeprazole	Omeprazole	250	78
Simvastatin	Simvastatin	242	74
Rosuvastatin Calcium	Rosuvastatin Calcium	210	67
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	155	51
Hydrochlorothiazide	Hydrochlorothiazide	152	51
Gabapentin	Gabapentin	148	30
Tramadol Hcl	Tramadol Hcl	138	38
Glimepiride	Glimepiride	134	41
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	134	41
Meloxicam	Meloxicam	121	43
Albuterol Sulfate Hfa	Albuterol Sulfate	114	42
Montelukast Sodium	Montelukast Sodium	111	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	108	34
Ozempic	Semaglutide	106	21
Pantoprazole Sodium	Pantoprazole Sodium	106	33
Alprazolam	Alprazolam	105	23
Zolpidem Tartrate	Zolpidem Tartrate	100	16
Tamsulosin Hcl	Tamsulosin Hcl	96	27
Eliquis	Apixaban	95	30
Fluoxetine Hcl	Fluoxetine Hcl	90	29
Sertraline Hcl	Sertraline Hcl	90	27
Trazodone Hcl	Trazodone Hcl	90	31
Duloxetine Hcl	Duloxetine Hcl	71	22
Furosemide	Furosemide	68	26
Metoprolol Tartrate	Metoprolol Tartrate	66	23
Clonidine Hcl	Clonidine Hcl	65	20
Carvedilol	Carvedilol	64	24
Ezetimibe	Ezetimibe	64	23
Prednisone	Prednisone	63	41
Methylprednisolone	Methylprednisolone	57	50
Citalopram Hbr	Citalopram Hydrobromide	55	16
Potassium Chloride	Potassium Chloride	55	16
Ibuprofen	Ibuprofen	53	30
Allopurinol	Allopurinol	52	16
Amitriptyline Hcl	Amitriptyline Hcl	52	13
Diazepam	Diazepam	51	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	51	13
Clonazepam	Clonazepam	50	suppressed
Clopidogrel	Clopidogrel Bisulfate	50	17
Lorazepam	Lorazepam	50	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	50	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	46	19
Finasteride	Finasteride	45	11
Azithromycin	Azithromycin	44	33
Jardiance	Empagliflozin	43	14
Xarelto	Rivaroxaban	42	12
Amoxicillin	Amoxicillin	41	36
Sumatriptan Succinate	Sumatriptan Succinate	41	suppressed
Fenofibrate	Fenofibrate	36	suppressed
Tresiba Flextouch U-100	Insulin Degludec	36	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	35	29
Eszopiclone	Eszopiclone	34	suppressed
Paroxetine Hcl	Paroxetine Hcl	34	suppressed
Pravastatin Sodium	Pravastatin Sodium	34	suppressed
Tizanidine Hcl	Tizanidine Hcl	34	12
Valacyclovir	Valacyclovir Hcl	33	suppressed
Atenolol	Atenolol	32	suppressed
Terazosin Hcl	Terazosin Hcl	32	suppressed
Fluticasone Propionate	Fluticasone Propionate	31	13
Januvia	Sitagliptin Phosphate	30	suppressed
Spiriva Respimat	Tiotropium Bromide	29	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	27	suppressed
Buspirone Hcl	Buspirone Hcl	27	suppressed
Clobetasol Propionate	Clobetasol Propionate	27	suppressed
Meclizine Hcl	Meclizine Hcl	27	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	19
Fenofibrate	Fenofibrate Nanocrystallized	26	suppressed
Glipizide	Glipizide	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	14
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	25	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	25	suppressed
Trulicity	Dulaglutide	24	suppressed
Chlorthalidone	Chlorthalidone	23	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Acyclovir	Acyclovir	21	13
Betamethasone Dipropionate	Betamethasone Dipropionate	21	11
Droplet Pen Needle	Pen Needle, Diabetic	21	11
Escitalopram Oxalate	Escitalopram Oxalate	21	suppressed
Aripiprazole	Aripiprazole	20	suppressed
Cephalexin	Cephalexin	20	18
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	12
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Celecoxib	Celecoxib	19	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Amiodarone Hcl	Amiodarone Hcl	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Fluconazole	Fluconazole	17	suppressed
Glipizide Er	Glipizide	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Mounjaro	Tirzepatide	16	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Rizatriptan	Rizatriptan Benzoate	15	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	14	12
Novolog Flexpen	Insulin Aspart	14	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	14	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Estradiol	Estradiol	13	suppressed
Famotidine	Famotidine	13	suppressed
Jantoven	Warfarin Sodium	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Methylphenidate Er	Methylphenidate Hcl	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Ramipril	Ramipril	11	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error